Integra LifeSciences Holdings Corp. (IART) Given New $105.00 Price Target at Argus
Integra LifeSciences Holdings Corp. (NASDAQ:IART) had its price target raised by equities researchers at Argus from $90.00 to $105.00 in a research report issued to clients and investors on Friday. The firm presently has a “buy” rating on the stock. Argus’ price objective would suggest a potential upside of 20.44% from the stock’s current price.
IART has been the subject of several other research reports. Barclays PLC upped their price objective on Integra LifeSciences Holdings Corp. from $74.00 to $77.00 and gave the company an “equal weight” rating in a research note on Thursday, June 2nd. Jefferies Group upped their price objective on Integra LifeSciences Holdings Corp. from $81.00 to $95.00 and gave the company a “buy” rating in a research note on Friday, July 29th. JPMorgan Chase & Co. began coverage on Integra LifeSciences Holdings Corp. in a research note on Wednesday, July 13th. They issued an “overweight” rating for the company. Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $94.00 price objective (up previously from $86.00) on shares of Integra LifeSciences Holdings Corp. in a research note on Sunday, August 21st. Finally, Zacks Investment Research raised Integra LifeSciences Holdings Corp. from a “hold” rating to a “buy” rating and set a $85.00 price objective for the company in a research note on Tuesday, June 28th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $86.13.
Shares of Integra LifeSciences Holdings Corp. (NASDAQ:IART) traded down 0.31% during midday trading on Friday, reaching $86.91. 62,871 shares of the company’s stock were exchanged. The stock has a market cap of $3.25 billion, a PE ratio of 359.13 and a beta of 0.52. Integra LifeSciences Holdings Corp. has a 12 month low of $54.75 and a 12 month high of $88.86. The company’s 50 day moving average is $85.61 and its 200-day moving average is $75.91.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/23/integra-lifesciences-holdings-corp-iart-given-new-105-00-price-target-at-argus.html
Integra LifeSciences Holdings Corp. (NASDAQ:IART) last issued its earnings results on Thursday, July 28th. The company reported $0.79 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.76 by $0.03. The firm earned $249.30 million during the quarter, compared to the consensus estimate of $243.17 million. Integra LifeSciences Holdings Corp. had a return on equity of 15.41% and a net margin of 0.79%. The business’s quarterly revenue was up 17.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.79 earnings per share. Equities analysts forecast that Integra LifeSciences Holdings Corp. will post $3.48 EPS for the current fiscal year.
In other Integra LifeSciences Holdings Corp. news, CEO Peter J. Arduini sold 24,009 shares of the stock in a transaction that occurred on Tuesday, August 9th. The stock was sold at an average price of $84.52, for a total transaction of $2,029,240.68. Following the transaction, the chief executive officer now directly owns 29,602 shares in the company, valued at approximately $2,501,961.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Richard D. Gorelick sold 4,000 shares of the stock in a transaction that occurred on Monday, August 1st. The stock was sold at an average price of $84.60, for a total value of $338,400.00. Following the transaction, the vice president now owns 9,702 shares in the company, valued at $820,789.20. The disclosure for this sale can be found here. 22.00% of the stock is owned by corporate insiders.
Institutional investors have recently bought and sold shares of the company. Societe Generale acquired a new position in Integra LifeSciences Holdings Corp. during the second quarter worth about $106,000. First Manhattan Co. acquired a new position in Integra LifeSciences Holdings Corp. during the second quarter worth about $135,000. BlackRock Inc. boosted its position in Integra LifeSciences Holdings Corp. by 137.2% in the first quarter. BlackRock Inc. now owns 2,016 shares of the company’s stock worth $136,000 after buying an additional 1,166 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in Integra LifeSciences Holdings Corp. by 718.0% in the second quarter. Tower Research Capital LLC TRC now owns 2,454 shares of the company’s stock worth $196,000 after buying an additional 2,154 shares during the last quarter. Finally, Strs Ohio boosted its position in Integra LifeSciences Holdings Corp. by 107.1% in the second quarter. Strs Ohio now owns 2,900 shares of the company’s stock worth $231,000 after buying an additional 1,500 shares during the last quarter. Hedge funds and other institutional investors own 88.32% of the company’s stock.
Integra LifeSciences Holdings Corp. Company Profile
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing and marketing of surgical implants and medical instruments. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery. Its segments include Specialty Surgical Solutions, which offers products, including specialty surgical instrumentation for a range of specialties.
Receive News & Ratings for Integra LifeSciences Holdings Corp. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Integra LifeSciences Holdings Corp. and related companies with MarketBeat.com’s FREE daily email newsletter.